Acrivon Therapeutics Future Growth
Future criteria checks 2/6
Acrivon Therapeutics's earnings are forecast to decline at 0.05% per annum while its annual revenue is expected to grow at 72.7% per year. EPS is expected to grow by 12.3% per annum.
Key information
-0.05%
Earnings growth rate
12.3%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 72.7% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 14 Nov 2024 |
Recent future growth updates
Recent updates
We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate
Nov 17
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
Sep 18Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?
Jul 17Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Mar 29Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Oct 05Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Jun 22We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Feb 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 29 | -114 | -101 | N/A | 8 |
| 12/31/2025 | 1 | -108 | -93 | -107 | 10 |
| 12/31/2024 | N/A | -82 | -76 | -71 | 10 |
| 9/30/2024 | N/A | -77 | -64 | -61 | N/A |
| 6/30/2024 | N/A | -69 | -55 | -53 | N/A |
| 3/31/2024 | N/A | -64 | -50 | -48 | N/A |
| 12/31/2023 | N/A | -60 | -44 | -43 | N/A |
| 9/30/2023 | N/A | -50 | -40 | -40 | N/A |
| 6/30/2023 | N/A | -45 | -37 | -36 | N/A |
| 3/31/2023 | N/A | -37 | -35 | -33 | N/A |
| 12/31/2022 | N/A | -31 | -32 | -30 | N/A |
| 9/30/2022 | N/A | -27 | -26 | -24 | N/A |
| 6/30/2022 | N/A | -20 | -22 | -20 | N/A |
| 3/31/2022 | N/A | -19 | -19 | -18 | N/A |
| 12/31/2021 | N/A | -16 | -14 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACRV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACRV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACRV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACRV's revenue (72.7% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: ACRV's revenue (72.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ACRV's Return on Equity is forecast to be high in 3 years time